Targeting redox-active pyridinium cations to mitochondria to inhibit proliferation of drug-resistant cancer cells
US12358935B2 · kind B2 · utility
0Cited by
1References
27Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Nov 1, 2019 |
| Grant date | Jul 15, 2025 |
| Priority date | — |
| Expiry date | Apr 15, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides novel mito-pyridinium compounds, prodrugs and the uses thereof for the treatment of cancer, particularly drug resistant cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.